Gary Raskob to Cost-Benefit Analysis
This is a "connection" page, showing publications Gary Raskob has written about Cost-Benefit Analysis.
Connection Strength
0.471
-
The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec; 124(6 Suppl):393S-396S.
Score: 0.218
-
A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20.
Score: 0.055
-
Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003; 21(7):477-96.
Score: 0.051
-
Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Curr Opin Pulm Med. 1996 Jul; 2(4):305-10.
Score: 0.033
-
Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol. 1995 Sep; 2(5):372-9.
Score: 0.031
-
Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
Score: 0.030
-
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2013 Apr; 32(2):111-260.
Score: 0.026
-
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94.
Score: 0.008
-
Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303.
Score: 0.008
-
Prophylaxis of venous thromboembolism. An overview. Chest. 1986 May; 89(5 Suppl):374S-383S.
Score: 0.004
-
The diagnosis of clinically suspected venous thrombosis. Clin Chest Med. 1984 Sep; 5(3):439-56.
Score: 0.004
-
A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA. 1984 Jul 13; 252(2):235-9.
Score: 0.004